Drospirenon v evolyutsiigormonal'noy kontratseptsii
- Authors: Mezhevitinova E.A.1, Sasunova R.A.1, Ivanova E.V.1, Ledina A.V.1
-
Affiliations:
- Issue: Vol 13, No 2 (2011)
- Pages: 16-19
- Section: Articles
- URL: https://gynecology.orscience.ru/2079-5831/article/view/28147
- ID: 28147
Cite item
Full Text
Abstract
About the authors
Elena Anatol'evna Mezhevitinova
Rimma Anatol'evna Sasunova
Elena Vladimirovna Ivanova
Antonina Vitalievna Ledina
References
- Прилепская В.Н., Межевитинова Е.А. Гормональная контрацепция, 2011.
- Прилепская В.Н., Бостанджян Л.Л. Гормональная контрацепция: от эволюции прогестагенов к новым возможностям. Гинекология, 2007; 6: 20-3.
- Андреева Е.Н., Карпова Е.А., Пономарева Т.А. Дроспиренон - проге- стаген с антиминералкортикоидными свойствами. Акушерство и гинекология, 2004; 6: 51-2.
- Пасман Н.М. Дроспиренон - гестаген ХХI века с антиминерало- кортикоидной активностью. Гинекология, 2004; 2: 92-6.
- Motivala A, Pitt B., Drospirenone for Oral Contraception and Hormone Replacement Therapy. Are its Cardiovascular Risks and Benefits the Same as Other Progestogens? Drugs 2007; 7 (5): 47-65.
- Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review, Mol Cell Endocrinol 2004; 217 (1-2): 255-61.
- Kulier R, Helmerhorst FM, Maitra N et al. Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review. Reprod Health 2004; 1 (1): 1.
- Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen, Contraception 2000 61 (2): 105-11.
- Apter D, Borsos A, Baumgдrtner W et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003; 8 (1): 37-51.
- Bitzer J, Paoletti AM., Added benefits and user satisfaction with a lowdose oral contraceptive containing drospirenone: results of three multicentre trials, Clin Drug Investig. 2009; 29 (2): 73-8.
- Gruber DM, Huber JC, Melis GB et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 mug and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20 mug and desogestrel 150 mug. Treat Endocrinol 2006; 5 (2): 115-21.
- Аганезова Н.В., Линде В.А., Клинический опыт применения комби- нированного монофазного орального контрацептива с дроспире- ноном при синдроме предменструального напряжения. Проблемы репродукции, 2008; 1: 66-72.
- Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (Suppl 9): 729-41.
- Сасунова Р.А., Межевитинова Е.А., Предменструальный синдром. Гинекология, 2010; 6 (12), 34-8.
- van Vloten WA, van Haselen CW, van Zuuren EJ et al. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69 (Suppl. 4): 2-15.
- Соболева Е.Л. Комбинированные оральные контрацептивы, со- держащие дроспиренон или ципротерона ацетат, в терапии угре- вой сыпи. Журн. акушерства и женских болезней, 2009; 2: 53-6.
- Gaspard U, Endrikat J, Desager JP et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004; 69 (4): 271-8.
- Foidart JM, Wuttke W, Bouw GM et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5 (2): 124-34.
- Huber J, Foidart JM, Wuttke W et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5 (1): 25-34.